Immunoprecise Antibodies Stock Probability of Future Stock Price Finishing Over 0.66
| IPA Stock | USD 0.38 0.03 8.57% |
Immunoprecise |
Immunoprecise Antibodies Target Price Odds to finish over 0.66
The tendency of Immunoprecise Stock price to converge on an average value over time is a known aspect in finance that investors have used since the beginning of the stock market for forecasting. However, many studies suggest that some traded equity instruments are consistently mispriced before traders' demand and supply correct the spread. One possible conclusion to this anomaly is that these stocks have additional risk, for which investors demand compensation in the form of extra returns.
| Current Price | Horizon | Target Price | Odds to move over $ 0.66 or more in 90 days |
| 0.38 | 90 days | 0.66 | about 25.25 |
Based on a normal probability distribution, the odds of Immunoprecise Antibodies to move over $ 0.66 or more in 90 days from now is about 25.25 (This Immunoprecise Antibodies probability density function shows the probability of Immunoprecise Stock to fall within a particular range of prices over 90 days) . Probability of Immunoprecise Antibodies price to stay between its current price of $ 0.38 and $ 0.66 at the end of the 90-day period is about 69.96 .
Considering the 90-day investment horizon Immunoprecise Antibodies has a beta of -1.4. This usually indicates as returns on its benchmark rise, returns on holding Immunoprecise Antibodies are expected to decrease by similarly larger amounts. On the other hand, during market turmoils, Immunoprecise Antibodies is expected to outperform its benchmark. Additionally Immunoprecise Antibodies has a negative alpha, implying that the risk taken by holding this instrument is not justified. The company is significantly underperforming the Dow Jones Industrial. Immunoprecise Antibodies Price Density |
| Price |
Predictive Modules for Immunoprecise Antibodies
There are currently many different techniques concerning forecasting the market as a whole, as well as predicting future values of individual securities such as Immunoprecise Antibodies. Regardless of method or technology, however, to accurately forecast the stock market is more a matter of luck rather than a particular technique. Nevertheless, trying to predict the stock market accurately is still an essential part of the overall investment decision process. Using different forecasting techniques and comparing the results might improve your chances of accuracy even though unexpected events may often change the market sentiment and impact your forecasting results.Immunoprecise Antibodies Risk Indicators
For the most part, the last 10-20 years have been a very volatile time for the stock market. Immunoprecise Antibodies is not an exception. The market had few large corrections towards the Immunoprecise Antibodies' value, including both sudden drops in prices as well as massive rallies. These swings have made and broken many portfolios. An investor can limit the violent swings in their portfolio by implementing a hedging strategy designed to limit downside losses. If you hold Immunoprecise Antibodies, one way to have your portfolio be protected is to always look up for changing volatility and market elasticity of Immunoprecise Antibodies within the framework of very fundamental risk indicators.α | Alpha over Dow Jones | -0.83 | |
β | Beta against Dow Jones | -1.4 | |
σ | Overall volatility | 0.12 | |
Ir | Information ratio | -0.17 |
Immunoprecise Antibodies Alerts and Suggestions
In today's market, stock alerts give investors the competitive edge they need to time the market and increase returns. Checking the ongoing alerts of Immunoprecise Antibodies for significant developments is a great way to find new opportunities for your next move. Suggestions and notifications for Immunoprecise Antibodies can help investors quickly react to important events or material changes in technical or fundamental conditions and significant headlines that can affect investment decisions.| Immunoprecise Antibodies generated a negative expected return over the last 90 days | |
| Immunoprecise Antibodies has high historical volatility and very poor performance | |
| Immunoprecise Antibodies has some characteristics of a very speculative penny stock | |
| Immunoprecise Antibodies has a very high chance of going through financial distress in the upcoming years | |
| The company reported the last year's revenue of 24.52 M. Reported Net Loss for the year was (27.18 M) with profit before taxes, overhead, and interest of 11.56 M. | |
| Immunoprecise Antibodies has about 19.24 M in cash with (4.25 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 0.77, which can makes it an attractive takeover target, given it will continue generating positive cash flow. | |
| Immunoprecise Antibodies has a poor financial position based on the latest SEC disclosures | |
| Roughly 12.0% of the company shares are held by company insiders | |
| Latest headline from finance.yahoo.com: Marcus Millichaps Institutional Property Advisors Brokers Three Multifamily Property Sales in Tacoma for 102.6 Million |
Immunoprecise Antibodies Price Density Drivers
Market volatility will typically increase when nervous long traders begin to feel the short-sellers pressure to drive the market lower. The future price of Immunoprecise Stock often depends not only on the future outlook of the current and potential Immunoprecise Antibodies' investors but also on the ongoing dynamics between investors with different trading styles. Because the market risk indicators may have small false signals, it is better to identify suitable times to hedge a portfolio using different long/short signals. Immunoprecise Antibodies' indicators that are reflective of the short sentiment are summarized in the table below.
| Common Stock Shares Outstanding | 25.6 M | |
| Cash And Short Term Investments | 3.5 M |
Immunoprecise Antibodies Technical Analysis
Immunoprecise Antibodies' future price can be derived by breaking down and analyzing its technical indicators over time. Immunoprecise Stock technical analysis helps investors analyze different prices and returns patterns as well as diagnose historical swings to determine the real value of Immunoprecise Antibodies. In general, you should focus on analyzing Immunoprecise Stock price patterns and their correlations with different microeconomic environments and drivers.
Immunoprecise Antibodies Predictive Forecast Models
Immunoprecise Antibodies' time-series forecasting models is one of many Immunoprecise Antibodies' stock analysis techniques aimed to predict future share value based on previously observed values. Time-series forecasting models are widely used for non-stationary data. Non-stationary data are called the data whose statistical properties, e.g., the mean and standard deviation, are not constant over time, but instead, these metrics vary over time. This non-stationary Immunoprecise Antibodies' historical data is usually called time series. Some empirical experimentation suggests that the statistical forecasting models outperform the models based exclusively on fundamental analysis to predict the direction of the stock market movement and maximize returns from investment trading.
Things to note about Immunoprecise Antibodies
Checking the ongoing alerts about Immunoprecise Antibodies for important developments is a great way to find new opportunities for your next move. Our stock alerts and notifications screener for Immunoprecise Antibodies help investors to be notified of important events, changes in technical or fundamental conditions, and significant headlines that can affect investment decisions.
| Immunoprecise Antibodies generated a negative expected return over the last 90 days | |
| Immunoprecise Antibodies has high historical volatility and very poor performance | |
| Immunoprecise Antibodies has some characteristics of a very speculative penny stock | |
| Immunoprecise Antibodies has a very high chance of going through financial distress in the upcoming years | |
| The company reported the last year's revenue of 24.52 M. Reported Net Loss for the year was (27.18 M) with profit before taxes, overhead, and interest of 11.56 M. | |
| Immunoprecise Antibodies has about 19.24 M in cash with (4.25 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 0.77, which can makes it an attractive takeover target, given it will continue generating positive cash flow. | |
| Immunoprecise Antibodies has a poor financial position based on the latest SEC disclosures | |
| Roughly 12.0% of the company shares are held by company insiders | |
| Latest headline from finance.yahoo.com: Marcus Millichaps Institutional Property Advisors Brokers Three Multifamily Property Sales in Tacoma for 102.6 Million |
Check out Immunoprecise Antibodies Backtesting, Immunoprecise Antibodies Valuation, Immunoprecise Antibodies Correlation, Immunoprecise Antibodies Hype Analysis, Immunoprecise Antibodies Volatility, Immunoprecise Antibodies History as well as Immunoprecise Antibodies Performance. For information on how to trade Immunoprecise Stock refer to our How to Trade Immunoprecise Stock guide.You can also try the Latest Portfolios module to quick portfolio dashboard that showcases your latest portfolios.
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Immunoprecise Antibodies. If investors know Immunoprecise will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Immunoprecise Antibodies listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (0.77) | Revenue Per Share 0.921 | Quarterly Revenue Growth (0.07) | Return On Assets (0.13) | Return On Equity (0.64) |
The market value of Immunoprecise Antibodies is measured differently than its book value, which is the value of Immunoprecise that is recorded on the company's balance sheet. Investors also form their own opinion of Immunoprecise Antibodies' value that differs from its market value or its book value, called intrinsic value, which is Immunoprecise Antibodies' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Immunoprecise Antibodies' market value can be influenced by many factors that don't directly affect Immunoprecise Antibodies' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Immunoprecise Antibodies' value and its price as these two are different measures arrived at by different means. Investors typically determine if Immunoprecise Antibodies is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Immunoprecise Antibodies' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.